e-learning
resources
European Respiratory Review
2019
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis
Bridget F. Collins, Ganesh Raghu
Source:
Eur Respir Rev, 28 (153) 190022; 10.1183/16000617.0022-2019
Journal Issue:
September
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Bridget F. Collins, Ganesh Raghu. Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis. Eur Respir Rev, 28 (153) 190022; 10.1183/16000617.0022-2019
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Related content which might interest you:
Anti-fibrotic effects of pirfenidone in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
Antifibrotic treatment in progressive non-IPF fibrotic interstitial lung diseases
Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis
Year: 2019
Aquoaporin-1 expression in idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Diffuse pulmonary fibrosis
Year: 2013
Antifibrotic choice in idiopathic pulmonary fibrosis
Source: International Congress 2018 – Idiopathic interstital pneumonias other than idiopathic pulmonary fibrosis (IPF)
Year: 2018
Current and future therapeutic approaches in idiopathic pulmonary fibrosis
Source: Eur Respir J 2005; 26: 693-703
Year: 2005
Beyond idiopathic pulmonary fibrosis: the world of progressive-fibrosing interstitial lung disease
Source: Eur Respir Rev, 27 (150) 180110; 10.1183/16000617.0110-2018
Year: 2018
Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
Clinical efficacy of pirfenidone in patients with severe fibrosing interstitial pneumonia
Source: International Congress 2015 – Treatment of IPF
Year: 2015
Genomic comparison of fibrotic rheumatoid arthritis-associated ILD and idiopathic pulmonary fibrosis
Source: International Congress 2015 – Connective tissue disorders
Year: 2015
Significance of histopathologic features suggesting connective tissue disease in idiopathic pulmonary fibrosis
Source: International Congress 2015 – Connective tissue disorders
Year: 2015
Negative outcome of prednisone in possible idiopathic pulmonary fibrosis
Source: International Congress 2016 – IPF clinical
Year: 2016
Fibulin-1 is a novel biomarker of disease severity in pulmonary fibrosis
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities
Year: 2013
Pirfenidone in idiopathic pulmonary fibrosis
Source: Eur Respir J 2010; 36: 695-696
Year: 2010
Pirfenidone in idiopathic pulmonary fibrosis
Source: Eur Respir J 2010; 35: 821-829
Year: 2010
17(R)-resolvinD1 improves MMP-9/TIMP-1 imbalance leading to amelioration of pulmonary fibrosis in mice
Source: International Congress 2016 – ILD pathogenesis
Year: 2016
Non-pulmonary comorbidities in idiopathic pulmonary fibrosis
Source: International Congress 2015 – IPF: clinical aspects
Year: 2015
Pirfenidone treatment in idiopathic pulmonary fibrosis: An Italian case series
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view
Year: 2013
Role of midkine in idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view
Year: 2013
Pulmonary hypertension in interstitial lung disease
Source: Eur Respir J 2008; 31: 1357-1367
Year: 2008
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept